Histopathology of pembrolizumab-induced hepatitis: a case report

Pathology. 2017 Dec;49(7):789-792. doi: 10.1016/j.pathol.2017.07.010. Epub 2017 Nov 1.

Authors

Karina Aivazian¹, Georgina V Long², Elizabeth C Sinclair³, James G Kench⁴, Catriona A McKenzie⁴

Affiliations

¹ Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Australia. Electronic address: k.aivazian@gmail.com.
² Melanoma Institute Australia, Australia; University of Sydney, Australia; Royal North Shore Hospital, Australia.
³ Douglass Hanly Moir Pathology, Sydney, NSW, Australia.
⁴ Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Australia; University of Sydney, Australia.

PMID: 29079004
DOI: 10.1016/j.pathol.2017.07.010

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / adverse effects*
Antibodies, Monoclonal, Humanized / therapeutic use
Chemical and Drug Induced Liver Injury / diagnosis
Chemical and Drug Induced Liver Injury / pathology*
Hepatitis / diagnosis
Hepatitis / pathology*
Humans
Male
Melanoma / complications
Melanoma / drug therapy*
Melanoma / genetics
Scleroderma, Diffuse / complications*

Substances

Antibodies, Monoclonal, Humanized
pembrolizumab